Arrowhead Says ARC-LPA Achieved 98% Knockdown, Long Duration of Effect After Subcutaneous Admin
May 06, 2016 at 12:00 PM EDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a poster on ARC-LPA, its preclinical development program targeting ...